Last reviewed · How we verify
CBLB502
At a glance
| Generic name | CBLB502 |
|---|---|
| Also known as | Entolimod |
| Sponsor | BioLab 612 LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination (PHASE2)
- Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery (PHASE1)
- Entolimod, an Adjuvant for Vaccine Augmentation (EARLY_PHASE1)
- Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer (PHASE2)
- Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBLB502 CI brief — competitive landscape report
- CBLB502 updates RSS · CI watch RSS
- BioLab 612 LLC portfolio CI